2017-11-13T16:50:55-06:00 2016-12-31 560747981 DIXON HUGHES GOODMAN LLP 901 EAST CARY STREET SUITE 1000 RICHMOND VA 23219 990 2016-01-01 521986675 FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC FOUN 3014025311 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 MARIA C FREIRE PHD PRESIDENT 3014025311 2017-11-13 1 LORI K COCHRAN P00853221 8042827636 204.15.98.225 2017-11-13 09:49:36 ES P 02C8C3F183F5FDB5309CFB0B1C4488420EC65632 303EF2475A1EB3281267E578719A17A3ACA1DFA4 2016 2017-02-10 21:41:12Z MARIA C FREIRE PHD 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 144276654 0 X HTTP://WWW.FNIH.ORG X 2001 MD THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES. 27 26 48 0 0 0 33961606 82860385 194500 122392 385451 479385 24552 64980 34566109 83527142 43310618 23228128 0 0 6530244 6221610 0 0 186542 9228745 17947728 59069607 47397466 -24503498 36129676 74645303 116383923 8169755 13155593 66475548 103228330 X SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. 0 0 41864088 22181298 122392 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPSPROGRAM ONE - RESEARCH PARTNERSHIPS -BUILDING DIALOGUE, CONSENSUS AND SOLUTIONS FOR HEALTH THREATS AROUND THE WORLDIN THE EARLY 21ST CENTURY, THE 10/90 GAP WAS AT THE FOREFRONT OF CONVERSATION WITHIN THE GLOBAL HEALTH COMMUNITY. THE GLOBAL FORUM ON HEALTH RESEARCH ASSERTED THAT JUST 10 PERCENT OF MEDICAL RESEARCH WAS DEVOTED TO THE DISEASES THAT CAUSE 90 PERCENT OF THE WORLD'S HEALTH BURDEN. TO FILL THIS GAP, THERE WAS A CRITICAL NEED TO INCREASE RESEARCH ON DISEASES THAT CAUSE MILLIONS OF DEATHS IN THE DEVELOPING WORLD. THE FNIH JOINED THE EFFORT TO REDUCE THE 10/90 GAP IN 2003 AS A FOUNDING MEMBER OF A PROGRAM THAT ADVANCED GLOBAL DISEASE RESEARCH ON A COLOSSAL SCALE. WITH AN INVESTMENT OF $200 MILLION FROM THE BILL & MELINDA GATES FOUNDATION, THE FNIH FORMED ITS LARGEST PARTNERSHIP CALLED THE GRAND CHALLENGES IN GLOBAL HEALTH INITIATIVE (GRAND CHALLENGES). THE GOAL OF THE INITIATIVE WAS TO ENCOURAGE APPLICATION OF THE LATEST SCIENTIFIC INNOVATIONS TO COMBAT THE MOST INTRACTABLE HEALTH PROBLEMS OF THE WORLD'S POOREST COUNTRIES. UNDER GRAND CHALLENGES, THE FNIH MANAGED 20 PROJECTS IN MORE THAN 25 COUNTRIES FOCUSED ON IMPROVING EXISTING AND DEVELOPING NEW VACCINES; CREATING STRATEGIES TO CONTROL THE TRANSMISSION OF DISEASES; DEVELOPING PHARMACEUTICALS AND DELIVERY SYSTEMS THAT MINIMIZE LIKELIHOOD OF RESISTANCE; AND GENERATING METHODS TO CURE CHRONIC INFECTIONS.BY 2016, THE FNIH'S CONTINUED PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION THAT FURTHERED THE WORK OF GRAND CHALLENGES HAD ADVANCED TWO HIGHLY NOVEL TECHNOLOGIES FOR PREVENTING THE SPREAD OF MOSQUITO-BORNE DISEASES TO FIELD TESTING, AND STIMULATED CONSENSUS BUILDING AROUND THE DEVELOPMENT PATHWAY FOR NEW MOSQUITO MODIFICATION TECHNOLOGIES. ELIMINATE DENGUE WAS ONE PROJECT THE FNIH INITIATED UNDER GRAND CHALLENGES. SCOTT O'NEILL, PH.D., THEN AT UNIVERSITY OF QUEENSLAND AND LATER AT MONASH UNIVERSITY, AUSTRALIA, RECEIVED A GRANT FOR RESEARCH IN 2005. SOON AFTER, HE HAD A BREAKTHROUGH MOMENT UPON DISCOVERY THAT THE COMMON WOLBACHIA BACTERIUM COULD BLOCK THE REPLICATION OF THE DENGUE VIRUS WITHIN AEDES AEGYPTI MOSQUITOES, WHICH ARE RESPONSIBLE FOR TRANSMITTING THE DISEASE. BY 2008, HE HAD PRODUCED MOSQUITOES THAT COULD CONSISTENTLY PASS WOLBACHIA TO THEIR OFFSPRING AND BLOCK VIRUS REPLICATION, THEREFORE INTERRUPTING TRANSMISSION OF THE DENGUE VIRUS TO HUMANS. ELIMINATE DENGUE WAS READY FOR SMALL SCALE OUTDOOR RELEASE OF THE MOSQUITOES IN AUSTRALIA BY 2011, VIETNAM BY 2013 AND INDONESIA BY 2014 IN COLLABORATION WITH LOCAL GOVERNMENTS.BY 2016, THE ZIKA VIRUS BECAME A PRIORITY HEALTH CONCERN WORLDWIDE AND ELIMINATE DENGUE RESEARCHERS HAD ANOTHER BREAKTHROUGH. THEY CONFIRMED THAT WOLBACHIA OBSTRUCTS THE SPREAD OF THE ZIKA VIRUS BY MOSQUITOES. SINCE THEN, THE WORLD HEALTH ORGANIZATION CALLED ON ELIMINATE DENGUE TO PROCEED WITH PILOT DEPLOYMENT OF THE TECHNOLOGY AND PROJECT TEAMS ARE SCALING-UP ACTIVITIES IN ANTIOQUIA, COLOMBIA AND RIO DE JANEIRO, BRAZIL.ANOTHER GRAND CHALLENGES GRANT SUPPORTED BY THE FNIH WAS AWARDED IN 2005 TO A PROJECT NOW CALLED TARGET MALARIA. THE PROJECT USES GENETIC MODIFICATION TECHNOLOGY (GENE DRIVE) TO REDUCE MOSQUITOES' ABILITY TO TRANSMIT PARASITES THAT CAUSE DISEASES SUCH AS MALARIA. THE ADVANCEMENT OF THIS TECHNOLOGY IS AT THE FOREFRONT OF GLOBAL DISCUSSIONS AS THE EMERGENCE OF SYSTEMS LIKE CRISPR/CAS9 ARE MAKING GENE DRIVE CONSTRUCTS EASIER TO BUILD. A GRANT WAS AWARDED TO AUSTIN BURT, PH.D., IMPERIAL COLLEGE LONDON, UK, AND HIS TEAM TO SUPPORT WAYS TO PROTECT PEOPLE FROM MALARIA-CARRYING MOSQUITOES. OVER THE NEXT DECADE AND WITH ADDITIONAL FUNDING THROUGH THE FNIH, PROF. BURT DEMONSTRATED THAT GENE DRIVES COULD BE USED TO REDUCE THE REPRODUCTION OF MALARIA MOSQUITOES. BY 2011, THE PROJECT ESTABLISHED FIELD SITES IN AFRICA, NOW COLLABORATING WITH SCIENTISTS IN BURKINA FASO, MALI AND UGANDA. TODAY, TARGET MALARIA CONTINUES TO REFINE ITS GENE DRIVE STRATEGY WITH THE GOAL OF CONTRIBUTING TO THE GLOBAL ERADICATION OF MALARIA. IN ONGOING PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION, PART OF THE FNIH'S ROLE HAS BEEN TO ENSURE THAT THE SCIENTIFIC COMMUNITY EXPLORED THE COMPLEX REGULATORY AND ETHICAL ISSUES SURROUNDING MOSQUITO MODIFICATION TECHNOLOGY. THE FNIH HELPED FUND A NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE STUDY THAT SUPPORTED FURTHER TESTING OF GENE DRIVE APPROACHES, WHILE RECOMMENDING A COLLABORATIVE AND CAUTIONARY APPROACH TO THE RESEARCH AND GOVERNANCE OF THESE TECHNOLOGIES. ADDITIONALLY, THE FNIH HOSTED THE "PROBLEM FORMULATION FOR USE OF GENE DRIVE TECHNOLOGY IN MOSQUITOES" WORKSHOP IN 2016. IT BROUGHT TOGETHER A DIVERSE GROUP OF INTERNATIONAL EXPERTS TO CONDUCT A SYSTEMATIC EVALUATION OF POTENTIAL RISKS ASSOCIATED WITH THE USE OF GENE DRIVE TECHNOLOGY TO REDUCE THE BURDEN OF MALARIA IN AFRICA AND TO CONSIDER THE POTENTIAL FOR UNINTENDED CONSEQUENCES. THIS WORKSHOP DEVELOPED CONSENSUS THAT WILL HELP INFORM THE DESIGN OF FURTHER RESEARCH, GUIDELINES AND REGULATIONS. GRAND CHALLENGES PROPELLED THE FNIH ONTO THE WORLD STAGE, SPURRING ITS RAPID GROWTH. THROUGH THE INITIATIVE, THE FNIH EXPANDED ITS INFRASTRUCTURE BY BRINGING GLOBALLY-RECOGNIZED SCIENTISTS TO THE TEAM AND ESTABLISHING ITS CAPACITY FOR GRANT MAKING. DUE LARGELY TO GRAND CHALLENGES, THE FNIH HAS BECOME INTERNATIONALLY RECOGNIZED FOR ITS INITIATIVES FOCUSED ON OPENING DIALOGUE, DEVELOPING CONSENSUS AND IMPLEMENTING SOLUTIONS FOR HEALTH THREATS THAT AFFECT PEOPLE AROUND THE GLOBE.THE BIOMARKERS CONSORTIUM: SHAPING THE FUTURE OF BIOMEDICAL RESEARCHTHE FNIH BIOMARKERS CONSORTIUM (BC) CELEBRATED 10 YEARS OF COLLABORATION, RESEARCH AND IMPACT ON REGULATORY SCIENCE IN 2016. THIS PUBLIC-PRIVATE PARTNERSHIP MANAGED BY THE FNIH IS HELPING TO CREATE A NEW ERA OF PRECISION MEDICINE AND TO ENABLE THERAPIES THAT ARE BETTER TAILORED FOR PATIENTS. IN 2016, THE BC LAUNCHED FIVE COLLABORATIVE PROJECTS, WHICH ARE DESIGNED TO GENERATE TOOLS THAT WILL ADVANCE THE DEVELOPMENT OF THERAPIES IN CANCER, RHEUMATOID ARTHRITIS, FRAILTY AND HEART DISEASE. CONSORTIUM MEMBERS ALSO CONTINUE TO DEVELOP NEW AND INNOVATIVE PROGRAMS IN THESE AND OTHER DISEASE AREAS ENSURING THE BC WILL PROVIDE DECISION-MAKING TOOLS FOR ADVANCING THERAPIES INTO THE FUTURE. IN ADDITION TO ITS WORK ON DISEASE-SPECIFIC PROJECTS, THE BC RECOGNIZED THAT THE USE OF BIOLOGICAL MARKERS (BIOMARKERS) IN DRUG DEVELOPMENT HAS BEEN PARTICULARLY HAMPERED BY A LACK OF CLEAR, PREDICTABLE AND SPECIFIC REGULATORY CRITERIA FOR THE EVIDENCE REQUIRED TO QUALIFY NEW MARKERS. TO RESOLVE THIS, A GROUP LED BY THE BC DEVELOPED AND RELEASED A "FRAMEWORK FOR DEFINING EVIDENTIARY CRITERIA FOR BIOMARKER QUALIFICATION" IN OCTOBER 2016 AS A TOOL TO HELP ASSESS THE LEVEL OF EVIDENCE NEEDED TO SUPPORT FORMAL REGULATORY QUALIFICATION OF BIOMARKERS AT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). THE DOCUMENT WAS A RESULT OF A MULTI-STAKEHOLDER EFFORT THAT INCORPORATED INPUT FROM NEARLY 200 SCIENTIFIC LEADERS FROM THE FDA, THE NATIONAL INSTITUTES OF HEALTH (NIH), THE FNIH, THE CRITICAL PATH INSTITUTE (C-PATH), PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) AND MULTIPLE PHARMACEUTICAL COMPANIES. THE FRAMEWORK WILL PROVE USEFUL IN ENABLING MORE PRODUCTIVE DISCUSSIONS BETWEEN BIOMARKER DEVELOPERS AND THE FDA, IMPROVING THE QUALITY OF BIOMARKER QUALIFICATION SUBMISSIONS AND INFORMING FUTURE EFFORTS TO DEVELOP RELEVANT FDA GUIDANCES FOR EVIDENTIARY CRITERIA IN BIOMARKER QUALIFICATION. OVER THE PAST DECADE, THE BC HAS RAISED MORE THAN $70 MILLION FOR PRECOMPETITIVE, COLLABORATIVE PROJECTS THAT INCLUDE PARTICIPANTS FROM THE NIH, THE FDA, NOT-FOR-PROFIT ORGANIZATIONS, ACADEMIC RESEARCH ORGANIZATIONS, AND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES. MORE THAN 20 PROJECTS HAVE BEEN LAUNCHED IN 13 DIFFERENT DISEASE AREAS, RESULTING IN 46 PUBLICATIONS WRITTEN ON BEHALF OF OR SPONSORED BY THE BC. ITS WORK ALSO HAS BEEN INSTRUMENTAL IN TESTING NEW MODELS FOR CLINICAL TRIALS. THE BC SPONSORED ONE OF THE FIRST TRIALS TO USE GENETIC MARKERS TO GUIDE THE SELECTION OF TREATMENTS FROM AMONG MULTIPLE DRUGS IN A SINGLE TRIAL, HELPING ESTABLISH AN ACCELERATED APPROVAL PATHWAY FOR NEW BREAST CANCER MEDICINES. TO DATE, THE WORK OF THE BC HAS SUPPORTED THE ADVANCEMENT OF SIX THERAPEUTICS IN THE DRUG DEVELOPMENT PROCESS AND HELPED GENERATE FOUR SEPARATE FDA GUIDANCE DOCUMENTS. THE BC CAN SOLVE THESE AND OTHER CHALLENGES HEAD-ON BECAUSE IT OFFERS A UNIQUE ENVIRONMENT IN WHICH THE RESOURCES AND SCIENTIFIC EXPERTISE OF ITS PARTNERS CAN BE FREELY SHARED. OVER THE PAST 10 YEARS, BIOMARKERS HAVE BECOME RECOGNIZED AS INDISPENSABLE TOOLS FOR EFFECTIVE DRUG DEVELOPMENT, AND THE BC HAS EQUALLY ESTABLISHED ITSELF AS THE PROVEN MODEL FOR ADVANCING THE SCIENTIFIC VALIDITY AND PRACTICAL UTILITY OF BIOMARKERS IN TREATING PATIENTS. ITS MISSION IS AS RELEVANT AS EVER. 1257933 987480 SEE SCHEDULE O, PROGRAM TWO, FELLOWSHIPS AND TRAINING PROGRAMSPROGRAM TWO - FELLOWSHIPS AND TRAINING PROGRAMS - BUILDING A CRITICAL PIPELINE OF CLINICIAN SCIENTISTSACCORDING TO THE AMERICAN MEDICAL ASSOCIATION, THE PERCENTAGE OF PHYSICIANS ENGAGED IN RESEARCH AND TEACHING HAS DECREASED IN PAST DECADES. THIS CONCERNING STATISTIC MEANS THAT THERE ARE FEWER CLINICIAN SCIENTISTS THAT PLAY THE VITAL ROLE OF UNDERSTANDING BASIC BIOLOGY AND SCIENTIFIC DISCOVERY WHILE CONSIDERING THE POTENTIAL BENEFITS TO PATIENTS. SINCE 1998, THE FNIH HAS HELPED BUILD A PIPELINE OF CLINICIAN SCIENTISTS BY SUPPORTING TRAINING PROGRAMS AND FELLOWSHIPS AT THE NATIONAL INSTITUTES OF HEALTH (NIH). THIS WORK BEGAN BY RAISING PRIVATE FUNDS FOR THE NIH CLINICAL RESEARCH TRAINING PROGRAM (CRTP). FOR MORE THAN A DECADE, THE PROGRAM ATTRACTED RESEARCH-ORIENTED MEDICAL, DENTAL AND VETERINARY STUDENTS TO RECEIVE TRAINING AT THE NIH. AN ANALYSIS OF THE PROGRAM FOUND THAT CRTP FOSTERED STUDENT CAREERS, AS NEARLY TWO-THIRDS OF PARTICIPANTS ARE STILL CONDUCTING CLINICAL RESEARCH. TRAINING AT THE NIH CONTINUES THROUGH FNIH-SUPPORTED INITIATIVES, SUCH AS THE AMGEN SCHOLARS PROGRAM, SCHOLAR EDUCATION FUNDED BY THE JAYNE KOSKINAS TED GIOVANIS FOUNDATION FOR HEALTH POLICY, THE SALLIE ROSEN KAPLAN POSTDOCTORAL FELLOWSHIP FOR WOMEN SCIENTISTS IN CANCER RESEARCH AND THE MEDICAL RESEARCH SCHOLARS PROGRAM (MRSP), WHICH HAS FURTHERED THE LEGACY OF CRTP SINCE 2012. IN 2016, 52 STUDENTS PARTICIPATING IN MRSP BEGAN ONE-YEAR TRAINING AT THE NIH, CONDUCTING RESEARCH PROJECTS WITH CLOSE MENTORSHIP FROM INVESTIGATORS IN AREAS INCLUDING CANCER, CARDIOLOGY AND NEUROLOGY. STUDENTS ALSO PARTICIPATED IN WORKSHOPS ON LEADERSHIP, ENTREPRENEURSHIP AND DRUG DEVELOPMENT, IN ADDITION TO CLINICAL TEACHING ROUNDS AT THE NIH CLINICAL CENTER. THE NIH AND THE PRIVATE SECTOR-WITH FUNDS RAISED THROUGH THE FNIH-HAVE SUPPORTED NEARLY 240 FELLOWS THROUGH THE MRSP TO DATE.BEYOND TRAINING PROGRAMS, THE FNIH FUNDS INDIVIDUAL FELLOWS IN THE LABORATORIES OF NIH RESEARCHERS ADVANCING THERAPIES FOR DISEASES SUCH AS CANCER. THE STEPHEN J. SOLARZ MEMORIAL FUND, ESTABLISHED IN 2010, HONORS FNIH BOARD MEMBER NINA SOLARZ'S LATE HUSBAND AND U.S. CONGRESSMAN WHO RECEIVED TREATMENT FOR ESOPHAGEAL CANCER AT THE NATIONAL CANCER INSTITUTE (NCI). THE FUND SUPPORTS FELLOWSHIPS IN THE LABORATORY OF DAVID SCHRUMP, M.D., CHIEF OF THE THORACIC AND GASTROINTESTINAL ONCOLOGY BRANCH IN THE CENTER FOR CANCER RESEARCH OF THE NCI, WHOSE RESEARCH STIMULATES A PATIENT'S IMMUNE SYSTEM INTO FIGHTING AND PREVENTING DIFFERENT TYPES OF NEW CANCER GROWTH. THE TWO-YEAR, FULLY FUNDED FELLOWSHIPS TRAIN POST-DOCTORATE SCIENTISTS AND RESEARCHERS FROM ABROAD SO THEY CAN RETURN TO THEIR HOME COUNTRIES WITH KNOWLEDGE THAT WILL BENEFIT THEIR LOCAL COMMUNITIES.ANOTHER FELLOWSHIP MANAGED BY THE FNIH FOCUSES ON RENAL CELL CANCER RESEARCH-THE MOST COMMON TYPE OF KIDNEY CANCER. THE DEAN R. O'NEILL RENAL CELL CANCER RESEARCH FUND AND THE DR. EDWARD T. RANCIC MEMORIAL FUND FOR CANCER RESEARCH HAVE SPONSORED THE FULL-TIME FELLOW FOR THE LAST 10 YEARS IN THE LABORATORY OF RICHARD W. CHILDS, M.D., SENIOR INVESTIGATOR, LABORATORY OF TRANSPLANTATION IMMUNOTHERAPY, AT THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE. SINCE 2007, LAB FELLOWS, INCLUDING CURRENT FELLOW EMILY LEVY, HAVE ADVANCED WORK IN RENAL CELL CANCER RESEARCH IN HOPES OF FINDING A CURE FOR KIDNEY CANCER.THESE TRAINING PROGRAMS AND FELLOWSHIPS ARE CRITICAL FOR DEVELOPING A PIPELINE OF CLINICIAN SCIENTISTS WHO ARE READY TO MEET THE DEMANDS OF THE CHANGING POPULATION. BUT BEYOND THIS, THEY WILL HELP FURTHER INNOVATION IN BIOMEDICAL RESEARCH FOR YEARS TO COME. 390128 59350 SEE SCHEDULE O, PROGRAM THREE, MEMORIALS, AWARDS AND EVENTSPROGRAM THREE - MEMORIALS, AWARDS AND EVENTS - THE FNIH MANAGES AND ORGANIZES SCIENTIFIC MEETINGS, AWARDS AND EVENTS THROUGHOUT THE YEAR. FROM LECTURES AND WORKSHOPS TO COLLABORATIVE SUMMITS, THE FNIH FACILITATED MORE THAN 60 EVENTS IN 2016 THAT SPANNED DOZENS OF FIELDS OF RESEARCH. THIS INCLUDED THE 5TH ANNUAL PRESENTATION OF THE LURIE PRIZE IN BIOMEDICAL SCIENCES, A $100,000 AWARD RECOGNIZING OUTSTANDING ACHIEVEMENT BY A PROMISING YOUNG SCIENTIST IN BIOMEDICAL RESEARCH. IN MAY 2017 THOUGHT LEADERS FROM THE NIH, PIONEERS IN BIOMEDICAL SCIENCE, THE BIOTECH AND PHARMACEUTICAL INDUSTRIES, PHILANTHROPISTS AND BUSINESS EXECUTIVES CONVENED AT THE ORGANIZATION OF AMERICAN STATES IN WASHINGTON, D.C. FOR THE PRESENTATION OF THE LURIE PRIZE AT THE FNIH AWARD CEREMONY. WOLF BLITZER, AWARD-WINNING JOURNALIST AND TELEVISION NEWS ANCHOR, WAS THE EVENING'S MASTER OF CEREMONIES. THE 2017 LURIE PRIZE WAS AWARDED TO DAVID M. SABATINI, M.D., PH.D., MEMBER OF THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH AND PROFESSOR OF BIOLOGY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY. DR. SABATINI DISCOVERED THE MTOR (MECHANISTIC TARGET OF RAPAMYCIN) CELLULAR PATHWAY AS A KEY REGULATOR OF GROWTH AND METABOLISM IN RESPONSE TO NUTRIENTS. 51627 PROGRAM FOUR - CAPITAL PROJECTS - THE FNIH'S CAPITAL PROJECTS ENHANCE THE RESEARCH ENVIRONMENT AT NIH, SUPPORTING AND PROMOTING THE IMPORTANT DISCOVERIES THAT RESULT FROM NIH'S LEADING-EDGE WORK. FOR EXAMPLE, THE FNIH SUPPORTS THE EDMOND J. SAFRA FAMILY LODGE, WHICH PROVIDES ACCOMMODATIONS TO ADULT PATIENTS RECEIVING CARE AT THE NIH CLINICAL CENTER AND THEIR FAMILIES AT NO COST TO THEM. IN ADDITION TO THEIR OWN PRIVATE ROOMS, GUESTS ARE FREE TO USE THE FAMILY LODGE'S MANY AMENITIES: A LIBRARY, A BUSINESS AND TELECOMMUTING CENTER, A FITNESS CENTER, A CHILDREN'S PLAY AREA, SEVERAL LOUNGE AREAS, A HEALING GARDEN, AND A NEWLY RENOVATED KITCHEN. THE FAMILY LODGE IS CONVENIENTLY LOCATED WITHIN WALKING DISTANCE OF THE NIH CLINICAL CENTER AND HAS SERVED THOUSANDS OF FAMILY MEMBERS AND CAREGIVERS. 51627 43563776 1 1 0 0 0 1 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 28 0 1 48 1 0 0 0 0 0 0 0 0 0 0 X 27 26 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD VA NY AL AK AR CA CO CT FL GA HI IL KS KY ME MA MI MS MN NH NJ NM NC ND OH OK OR PA RI SC TN UT WA WV WI X X DONALD M HILL 3014025311 9650 ROCKVILLE PIKE BETHESDA MD 20814 DR STEVEN M PAUL CHAIRMAN 1.50 X X 0 0 0 MR STEVEN C MAYER TREASURER 2.00 X X 0 0 0 THE HON JOHN EDWARD PORTER VICE-CHAIRMAN FOR POLICY 1.00 X X 0 0 0 DR SOLOMON H SNYDER VICE-CHAIRMAN FOR SCIENCE 0.50 X X 0 0 0 MRS WILLIAM MCCORMICK BLAIR JR SECRETARY 1.00 X X 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 40.00 X X 406597 0 26500 DR PAUL M MONTRONE BOARD OF DIRECTORS MEMBER 1.00 X 0 0 0 DAME JILLIAN SACKLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS LILY SAFRA BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR ELLEN V SIGAL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR CHARLES A SANDERS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS WILLIAM N CAFRITZ BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR SAMUEL O THIER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR MARTIN J MURPHY JR BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR KATHY BLOOMGARDEN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MS ANN LURIE BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR FREDA C LEWIS-HALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MS NINA SOLARZ BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JAMES H DONOVAN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL L HERRLING BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR RONALD L KRALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR EDISON T LIU BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR JUDY LANSING KOVLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JOEL S MARCUS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR RUSSELL W STEENBERG BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL STOFFELS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR THOMAS R INSEL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR JOSEPH M FECZKO BOARD OF DIRECTORS MEMBER 1/16-5/16 0.25 X 0 0 0 MS ANNE WOJCICKI BOARD OF DIRECTORS MEMBER 1/16-5/16 0.25 X 0 0 0 DR STEPHANIE JAMES DIRECTOR OF SCIENCE 40.00 X 305588 0 26500 MR DAVID WHOLLEY DIRECTOR OF RESEARCH PARTNERSHIPS 40.00 X 301988 0 38035 MS JULIE TUNE CHIEF FINANCIAL OFFICER 40.00 X 201681 0 31703 MS JULIA WOLF-RODDA DIRECTOR OF DEVELOPMENT 40.00 X 199264 0 31461 MR KEVIN A KLOCK DIR. OF OPERATIONS & PRESIDENT ADVISOR 40.00 X 199267 0 31462 DR JOSEPH MENETSKI DEPUTY DIRECTOR OF RESEARCH PARTNERSHIPS 40.00 X 200877 0 31527 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 40.00 X 169024 0 28437 DR MICHAEL GOTTLIEB ASSOCIATE DIRECTOR OF SCIENCE 40.00 X 160295 0 16030 DR ROSA CANET AVILES SCIENTIFIC PROGRAM MANAGER 40.00 X 157635 0 27298 MR STEVE HOFFMANN SCIENTIFIC PROGRAM MANAGER 40.00 X 144738 0 26009 2446954 0 314962 21 0 1 0 SWOG CTI 24 FRANK LLOYD WRIGHT DRIVE PO BOX ANN ARBOR MI 48105 CONDUCTS CLINICAL TRIAL FOR LUNGMAP 4129601 AVID RADIOPHARMACEUTICALS INC 3711 MARKET STREET 7TH FLOOR PHILADELPHIA PA 19104 CONDUCTS CLINICAL TRIAL FOR AMP AD 481500 BUSINESS TALENT GROUP LLC 406 BLACKWELL ST SUITE 240A DURHAM NC 27701 CONSULTING SERVICES FOR SUPPORT FUNCTION 467064 MARRIOTT BUSINESS SERVICES PO BOX 402642 ATLANTA GA 30384 MEETING SERVICES FOR VARIOUS PROJECTS 360908 ICON EARLY PHASE SERVICES LLC PO BOX 28939 NEW YORK NY 10087 CONDUCTS CLINICAL TRIAL FOR ABSSI CARP A 325674 16 15500 1150000 81694885 754570 82860385 ADMINISTRATIVE FEES 561000 122392 122392 122392 574125 574125 60455452 60550192 -94740 -94740 -94740 264300 15500 199320 64980 64980 83527142 122392 0 544365 22000760 22000760 8100 8100 1219268 1219268 1792412 747407 1026634 18371 3169479 1984475 1098349 86655 346472 186729 145025 14718 585472 352135 223935 9402 327775 158591 169184 120295 111052 9243 52935 52935 101900 31083 70817 7000 7000 25288 12293 12985 10 148799 66153 64991 17655 473081 189410 283671 1474382 1391423 78349 4610 20094 20094 190673 141179 49494 PROGRAM CONTRACTS 13538016 13538016 CONSULTANTS 1615064 1456645 152669 5750 HONORARIA 121600 121600 TEMPORARY SERVICES 96946 74011 22088 847 -38345 -233554 166685 28524 47397466 43563776 3647148 186542 21131272 46693317 10084867 26338796 84024 90770 692845 650240 50340 42605 43250167 43080177 44633 138258 74645303 116383923 1460257 8076645 5975257 4474530 577271 453876 156970 150542 8169755 13155593 X 11662389 13322940 51608294 86811639 3204865 3093751 66475548 103228330 74645303 116383923 36129676 623106 0 X X 0 1 X 1 0 X 58869026 59135001 73905546 33961607 82860385 308731565 58869026 59135001 73905546 33961607 82860385 308731565 154311898 154419667 140900 213728 214303 367897 574125 1510953 310242518 1208504 0.49770 0.46450 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2 2525 3100 3732287 1 1 0 1 X 9501571 11412 243278 52231 9704030 9616660 10356 -100829 24616 9501571 3381374 6271975 11641 48330 9616660 3491739 14559 -83704 41220 3381374 3498900 15153 25879 48193 3491739 0.64500 0.31880 0.03620 0 0 692845 650240 42605 42605 CHARITABLE GIFT ANNUITY 150542 150542 X 84602588 623106 253020 876126 83726462 -199320 -199320 83527142 47849806 253020 199320 452340 47397466 0 47397466 PART IV, LINE 2B: AS OF 12/31/2016, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC HELD $453,876 IN AGENCY FUNDS FOR FUTURE DISTRIBUTIONS TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED. PART V, LINE 4: THE FOUNDATION'S ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSES. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS. PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2016 AND 2015. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE -199,320. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE 199,320. 1 EUROPE 0 0 GRANTMAKING 933111 SOUTH ASIA 0 0 GRANTMAKING 286157 0 0 0 0 0 0 1219268 0 1219268 SOUTH ASIA MALNUTRITION & ENTERIC DISEASES NETWORK 144394 WIRE TRANSFER SOUTH ASIA MALNUTRITION & ENTERIC DISEASES NETWORK 101856 WIRE TRANSFER EUROPE AMP-T2 DIABETES 732435 WIRE TRANSFER EUROPE AMP-T2 DIABETES 85341 WIRE TRANSFER SOUTH ASIA EPIDEMIOLOGY OF VISCERAL LEISMANIASIS PROJECT 39907 WIRE TRANSFER EUROPE IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 115335 WIRE TRANSFER 5 1 0 0 0 0 0 0 PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. 2016 FNIH AWARD CEREMONY 279800 15500 264300 13000 186320 279800 15500 264300 13000 186320 199320 64980 1 CASE WESTERN RESERVE UNIVERSITY NORD HALL SUITE 615 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(C)(3) 338537 CTVIMC2-MOLECULAR IMMUNE CORRELATES CORE CATALYSIS FOUNDATION FOR HEALTH INC 1900 POWELL STREET SUITE 600 EMERYVILLE CA 94608 208602047 501(C)(3) 81141 PREDICT TB SUTTER BAY HOSPITALS DBA CALIFORNIA PACIFIC MEDICAL CENTER 475 BRANNAN STREET SUITE 220 SAN FRANCISCO CA 94107 940562680 501(C)(3) 63480 SARCOPENIA DONALD DANFORTH PLANT SCIENCE CENTER 975 NORTH WARSON ROAD ST LOUIS MO 63132 311584621 501(C)(3) 494937 REGULATORY DEVELOPMENT FOR HEG-MODIFIED MOSQUITOES DUKE UNIVERSITY 2200 WEST MAIN STREET SUITE 820 ERWIN SQUARE PLAZA DURHAM NC 27705 560532129 501(C)(3) 166655 PROFICIENCY TESTING CENTRAL/CTVIMC2 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 276523 CTVIMC2/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM FRIENDS OF CANCER RESEARCH 1800 M STREET NW SUITE 1050 SOUTH WASHINGTON DC 20036 521983273 501(C)(3) 150000 LUNGCANCER PROTOCOL HENRY JACKSON FOUNDATION (USMHRP) 1401 ROCKVILLE PIKE SUITE 600 ROCKVILLE MD 20852 521317896 501(C)(3) 108516 PROFICIENCY TESTING/MAL-ED ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 138240 AMP-T2 DIABETES-AMP AD JOHNS HOPKINS UNIVERSITY 615 N WOLFE ST W1100 BALTIMORE MD 21205 150595110 501(C)(3) 519047 MAL-ED/ CARDIAC TROPONIN NIH- CLINICAL CENTER 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 409690 RESEARCH NIHOD 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 198200 RESEARCH NIHNCI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 1017902 RESEARCH NIHNHLBI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 395919 RESEARCH NIHNIA 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 917915 RESEARCH NIHNIAAA 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858116 170(C)(1) GOVT 4831999 RESEARCH NIHNIAID 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 3525621 RESEARCH NIHNIAMS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 1860000 RESEARCH NIHNIMH 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 973456 RESEARCH NIHNINDS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 2780620 RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET 1040 WOLVERINE TOWER ANN ARBOR MI 48109 386006309 170(C)(1) GOVT 1792113 AMP-T2 DIABETES. DEPOSIT OF METSIM AND FUSION DATA INTO KNOWLEDGE PORTAL THE PENNYSLVANIA STATE UNIVERSITY 401 RIDER BLDG 227 W BEAVER AVE STATE COLLEGE PA 16801 246000376 170(C)(1) GOVT 37925 MAL-ED UNIVERSITY OF CALIFORNIA SAN FRANCISCO MISSION HALL 550 16TH STREET 2ND FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 140010 BONE QUALITY UNIVERSITY OF SOUTHERN CALIFORNIA SOTO STREET BUILDING 2001 SOTO STREET LOS ANGELES CA 900899235 911642394 501(C)(3) 436394 HD-SCA UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 546001796 170(C)(1) GOVT 344250 MAL-ED 25 AWARDS 6 8100 FMV PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. X X X 0 0 0 0 0 0 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 406597 0 0 0 0 0 26500 0 0 0 433097 0 0 0 DR STEPHANIE JAMES DIRECTOR OF SCIENCE 305588 0 0 0 0 0 26500 0 0 0 332088 0 0 0 MR DAVID WHOLLEY DIRECTOR OF RESEARCH PARTNERSHIPS 299438 0 0 0 2550 0 26500 0 11535 0 340023 0 0 0 MS JULIE TUNE CHIEF FINANCIAL OFFICER 201181 0 0 0 500 0 20168 0 11535 0 233384 0 0 0 MS JULIA WOLF-RODDA DIRECTOR OF DEVELOPMENT 197264 0 0 0 2000 0 19926 0 11535 0 230725 0 0 0 MR KEVIN A KLOCK DIR. OF OPERATIONS & PRESIDENT ADVIS 196684 0 0 0 2583 0 19927 0 11535 0 230729 0 0 0 DR JOSEPH MENETSKI DEPUTY DIRECTOR OF RESEARCH PARTNERS 200877 0 0 0 0 0 20088 0 11439 0 232404 0 0 0 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 165024 0 4000 0 0 0 16902 0 11535 0 197461 0 0 0 DR MICHAEL GOTTLIEB ASSOCIATE DIRECTOR OF SCIENCE 160295 0 0 0 0 0 16030 0 0 0 176325 0 0 0 DR ROSA CANET AVILES SCIENTIFIC PROGRAM MANAGER 155135 0 0 0 2500 0 15763 0 11535 0 184933 0 0 0 MR STEVE HOFFMANN SCIENTIFIC PROGRAM MANAGER 144738 0 0 0 0 0 14474 0 11535 0 170747 0 0 0 X 2 16902 STOCK PRICE X 2 737668 MARKET PRICE 0 0 0 FORM 990, PART III, LINE 4A CONTINUED: CHANGING THE PROGNOSIS OF ALZHEIMER'S DISEASE FIRST DISCOVERED 110 YEARS AGO, ALZHEIMER'S DISEASE STILL HAS NO CURE OR EFFECTIVE TREATMENT. MORE THAN FIVE MILLION AMERICANS SUFFER FROM THIS PROGRESSIVE BRAIN DISORDER, WITH ESTIMATES BY THE NATIONAL INSTITUTE ON AGING (NIA) SUGGESTING IT IS THE THIRD LEADING CAUSE OF DEATH FOR OLDER ADULTS. FOR YEARS, SCIENTISTS HAVE LABORED WITH LIMITED SUCCESS TO FIND BREAKTHROUGHS THAT WOULD AID IN THE DIAGNOSIS AND TREATMENT OF THIS DEVASTATING DISEASE. BUT IN 2004 AN UNPRECEDENTED STUDY CALLED THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)-WHICH ENTERED ITS THIRD PHASE IN 2016-UNITED SCIENTISTS ACROSS MULTIPLE SECTORS TO CHANGE THE PROGNOSIS FOR DEVELOPING NEW TREATMENTS. "THE PROBLEM IN THE FIELD WAS THAT YOU HAD MANY DIFFERENT SCIENTISTS, IN MANY DIFFERENT UNIVERSITIES, DOING THEIR OWN RESEARCH WITH THEIR OWN PATIENTS AND WITH THEIR OWN METHODS," MICHAEL W. WEINER, M.D., ADNI PRINCIPAL INVESTIGATOR, SAN FRANCISCO DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, TOLD THE NEW YORK TIMES IN 2010. "WHAT WAS NEEDED WAS TO GET EVERYONE TOGETHER AND TO GET A COMMON DATA SET." ADNI FULFILLED THIS NEED BY BRINGING THE PUBLIC AND PRIVATE SECTORS TOGETHER TO UNCOVER THE BIOLOGICAL MARKERS (BIOMARKERS) THAT TRACK ALZHEIMER'S DISEASE PROGRESSION. THE LONGITUDINAL STUDY USES IMAGING, BIOCHEMICAL AND GENETIC DATA TO IDENTIFY CHANGES TAKING PLACE IN THE BRAINS OF 800 INDIVIDUALS WITH NORMAL COGNITION AND DIFFERENT STAGES OF THE DISEASE. MOST SIGNIFICANTLY, THE DATA ARE MADE IMMEDIATELY AVAILABLE TO RESEARCHERS AT ANY ORGANIZATION. FULFILLING ITS UNIQUE AND INSTRUMENTAL ROLE, THE FNIH BROUGHT ALL OF THE NECESSARY PARTIES TOGETHER. BY THE LAUNCH OF THE FIRST PHASE OF ADNI, NIA CONTRIBUTED $41 MILLION, OTHER NATIONAL INSTITUTES OF HEALTH INSTITUTES PROVIDED $2.4 MILLION AND 20 COMPANIES AND TWO NOT-FOR-PROFIT ORGANIZATIONS DONATED $27 MILLION THROUGH THE FNIH. MORE THAN 30 ORGANIZATIONS HAVE SUPPORTED ADNI SINCE LAUNCH AND RESEARCHERS ARE TRACKING VOLUNTEERS AT 58 CLINICAL SITES IN NORTH AMERICA. THE THIRD PHASE OF ADNI (ADNI3) LAUNCHED IN SEPTEMBER 2016. NIA SUPPORT IS EXPECTED TO TOTAL $40 MILLION OVER THE COURSE OF ADNI3 AND AN ADDITIONAL $20 MILLION IS SOUGHT BY THE FNIH FROM THE PRIVATE SECTOR. ADDITIONS TO ADNI3 INCLUDE RECRUITING MORE PATIENT VOLUNTEERS, USING STATE-OF-THE-ART IMAGING TO MONITOR BRAIN LEVELS OF TAU (A PROTEIN THAT IS OFTEN ABNORMAL IN ALZHEIMER'S PATIENTS) AND PERFORMING CUTTING-EDGE ANALYSES TO ASSESS COMPLEX INTERACTIONS BETWEEN THE BRAIN AND BODY. ADNI3 ALSO WILL ASSESS COGNITIVE FUNCTION THROUGH COMPUTER TESTS AT HOME AND IN THE DOCTOR'S OFFICE. AFTER 12 YEARS, ADNI CONTINUES TO ADVANCE THE FIELD OF ALZHEIMER'S DISEASE, WHILE SERVING AS A MODEL FOR HOW PUBLIC-PRIVATE PARTNERSHIPS CAN LEAD TO OTHERWISE UNATTAINABLE RESEARCH PROGRESS. BY STANDARDIZING TECHNOLOGIES AND PROTOCOLS, ADNI HAS IMPROVED CLINICAL TRIAL DESIGN AND INFLUENCED THE DEVELOPMENT OF OTHER PARTNERSHIPS IN AREAS SUCH AS PARKINSON'S DISEASE AND MULTIPLE SCLEROSIS, AND ITS OPEN-ACCESS DATA POLICY SERVES AS A MODEL OF SUCCESSFUL PRECOMPETITIVE DATA SHARING. ADNI DATA HAVE BEEN DOWNLOADED FOR RESEARCH PURPOSES MORE THAN 14 MILLION TIMES AND SCIENTISTS WORLDWIDE HAVE USED THEM TO PUBLISH MORE THAN 1,200 SCIENTIFIC PAPERS, LEADING TO A BETTER UNDERSTANDING OF THE RELATIONSHIP BETWEEN BIOMARKERS AND ALZHEIMER'S DISEASE PROGRESSION-AND HOPEFULLY, ONE DAY SOON, NEW AND EFFECTIVE TREATMENTS. CELEBRATING 20 YEARS OF PARTNERSHIP AND DISCOVERY (TIMELINE) FOR TWO DECADES, THE FNIH HAS BUILT AND NURTURED SCIENTIFIC PARTNERSHIPS, RAISING NEARLY $1 BILLION TO MAKE IMPORTANT HEALTH DISCOVERIES POSSIBLE. THESE ALLIANCES WITH GOVERNMENT, ACADEMIA, INDUSTRY, PHILANTHROPISTS AND INDIVIDUAL DONORS, ENABLE THE FNIH TO SUPPORT RESEARCHER TRAINING, AWARDS, SYMPOSIA AND PATIENT CARE ACTIVITIES AT THE NATIONAL INSTITUTES OF HEALTH (NIH), IN ADDITION TO FOSTERING INNOVATIVE RESEARCH MODELS THAT PROPEL CUTTING-EDGE SCIENCE. THE FNIH'S SUCCESS IS A TESTAMENT TO THE POWER OF COLLABORATION AMONG DIVERSE STAKEHOLDERS WORKING TO SOLVE PRESSING HEALTH CHALLENGES TOGETHER. AS A TRUSTED RESOURCE FOR THE NIH AND THE SCIENTIFIC COMMUNITY, THE FNIH WILL CONTINUE TO LEAD EFFORTS TO SHAPE THE COURSE OF BIOMEDICAL SCIENCE AND HUMAN HEALTH FOR DECADES TO COME. 1998 - NORMAN P. SALZMAN MEMORIAL SYMPOSIUM AND AWARD IN VIROLOGY: FIRST ANNUAL AWARD IN FNIH HISTORY IS ESTABLISHED; 20 OUTSTANDING FELLOWS HONORED TO DATE. - CLINICAL RESEARCH TRAINING PROGRAM: MAJOR PROGRAM TO TRAIN CLINICIAN SCIENTISTS AT THE NIH IS LAUNCHED. 1999 - OSTEOARTHRITIS INITIATIVE: THE FNIH'S FIRST LARGE RESEARCH PROJECT THAT CREATED A PUBLIC-ACCESS DATABASE THAT ENABLED SCIENTISTS WORLDWIDE TO HELP PREDICT THE PROGRESSION OF OSTEOARTHRITIS AND DEVELOP TREATMENTS, LEADING TO A NEW MODEL FOR COLLABORATION. 2003 - ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI): WITH NEW MODELS FOR COLLABORATIVE RESEARCH AND OPEN DATA ACCESS, THIS STUDY ADVANCES THE UNDERSTANDING OF ALZHEIMER'S DISEASE OVER THE NEXT 12 YEARS. - GRAND CHALLENGES IN GLOBAL HEALTH: A $200 MILLION PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION TO FIGHT DISEASES IN THE WORLD'S POOREST COUNTRIES. 2005 - THE EDMOND J. SAFRA FAMILY LODGE: THIS HOME-AWAY-FROM-HOME FOR PATIENTS OF THE NIH CLINICAL CENTER AND THEIR FAMILIES OPENS. MORE THAN 110,000 ROOM NIGHTS HOSTED TO DATE. - GENETIC ASSOCIATION INFORMATION NETWORK (GAIN): SAMPLES FROM THOUSANDS OF PATIENTS IN SIX COMMON DISEASES ARE SEQUENCED AND COMPILED IN THE FIRST LARGE-SCALE INDIVIDUAL GENOTYPE-PHENOTYPE DATABASE (DBGAP) AT THE NATIONAL LIBRARY OF MEDICINE. - COMPREHENSIVE T-CELL VACCINE IMMUNE MONITORING CONSORTIUM (CTC-VIMC): A NETWORK ACROSS THREE CONTINENTS THAT PROVIDES RESEARCHERS WITH TOOLS TO EVALUATE PATIENTS FOR HIV/ AIDS VACCINES. 2006 - THE BIOMARKERS CONSORTIUM: THIS LANDMARK PUBLIC-PRIVATE PARTNERSHIP LAUNCHES TO ADVANCE THE QUALIFICATION OF NEW BIOMARKERS USED IN DRUG DEVELOPMENT AND APPROVALS. 2007 - OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP (OMOP): A PARTNERSHIP THAT STUDIES ADVERSE DRUG REACTIONS TO HELP IMPROVE THE SAFETY OF MEDICAL PRODUCTS. 2008 - MAL-ED: A LONGITUDINAL STUDY THAT EXAMINES THE RELATIONSHIPS BETWEEN MALNUTRITION AND INTESTINAL DISEASES AND THEIR EFFECT ON THE HEALTH AND DEVELOPMENT OF YOUNG CHILDREN. - VECTOR-BASED CONTROL OF TRANSMISSION: DISCOVERY RESEARCH (VCTR): A PROGRAM THAT DEVELOPS NOVEL TECHNOLOGIES TO STOP THE SPREAD OF MOSQUITO-BORNE DISEASES. 2012 - SPORTS AND HEALTH RESEARCH PROGRAM (SHRP): A PARTNERSHIP THAT ACCELERATES RESEARCH ON MEDICAL CONDITIONS PROMINENT IN ATHLETES, SUCH AS TRAUMATIC BRAIN INJURY. - MEDICAL RESEARCH SCHOLARS PROGRAM (MRSP): THIS INTENSIVE RESIDENTIAL TRAINING PROGRAM BEGINS AT THE NIH FOR MEDICAL, DENTAL AND VETERINARY STUDENTS. 2013 - LURIE PRIZE IN BIOMEDICAL SCIENCES: ESTABLISHMENT OF THIS ANNUAL AWARD THAT RECOGNIZES OUTSTANDING ACHIEVEMENTS BY A YOUNG BIOMEDICAL RESEARCHER. - ACCELERATING MEDICINES PARTNERSHIP (AMP): A $190 MILLION PARTNERSHIP THAT SEEKS TO IDENTIFY AND VALIDATE NEW DRUG TARGETS IN ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND IMMUNE-MEDIATED DISORDERS. - GENOME: UNLOCKING LIFE'S CODE: THE FNIH FUNDS THIS HUMAN GENOMICS EXHIBIT, WHICH IS NOW ON A FOUR-YEAR NORTH AMERICAN TOUR. - ELIMINATE DENGUE: A PROJECT THAT USES A COMMON BACTERIUM TO HELP STOP THE SPREAD OF VIRAL DISEASES BY MOSQUITOES. 2014 - LUNGMAP: A PRECISION MEDICINE TRIAL THAT TESTS MULTIPLE GENETICALLY-TARGETED DRUGS AND IMMUNOTHERAPIES. 2016 - EVIDENTIARY CRITERIA FRAMEWORK: THE FNIH BIOMARKERS CONSORTIUM WORKS WITH THE NIH AND FDA TO DEVELOP STANDARDS FOR THE LEVELS OF EVIDENCE REQUIRED TO QUALIFY BIOMARKERS FOR USE IN DRUG DEVELOPMENT. - CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD: AN ANNUAL AWARD THAT RECOGNIZES PERSONS AND/ OR ORGANIZATIONS THAT MAKE SIGNIFICANT CONTRIBUTIONS IN SUPPORT OF THE FNIH'S MISSION. FORM 990, PART VI, SECTION A, LINE 2 DR. FREIRE, PRESIDENT OF THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC. (FNIH), IS A NON-EXECUTIVE MEMBER OF THE BOARD OF DIRECTORS OF ALEXANDRIA REAL ESTATE EQUITIES (ARE). MR. JOEL MARCUS, CEO AND CHAIRMAN OF ARE IS A NON-EXECUTIVE MEMBER OF THE FNIH BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE FINAL FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. BOARD DIRECTORS SHALL BE PROVIDED WITH AT LEAST TEN BUSINESS DAYS TO REVIEW THE FORM AND RAISE QUESTIONS, MAKE SUGGESTIONS, AND ADDRESS ANY POTENTIAL PROBLEMS OR CONCERNS WITH THE CHIEF FINANCIAL OFFICER. A SPECIAL MEETING OF THE GOVERNANCE COMMITTEE WILL BE CALLED TO REVIEW THE SUGGESTED CHANGES FROM THE BOARD OF DIRECTORS AND TO APPROVE THE FINAL VERSION OF THE FORM 990 FOR SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, IN THE ABSENCE OF THE INTERESTED PERSON, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED. FORM 990, PART VI, SECTION B, LINE 15 BEGINNING IN 2015, THE NEWLY CREATED COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WILL REVIEW AND APPROVE THE SALARIES OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 ALL DOCUMENTS ARE AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE. FORM 990, PART XII, LINE 2C: PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.